GVIRF Webinar

New Tuberculosis Vaccines for Adults & Adolescents: *Progress, Prospects, and Perspectives*

22 February 2024, 09.00 – 12.30 Eastern Time (UTC -5)

Registration link will be posted at
https://www.technet-21.org/en/hot-topics-items/15105-gvirf

It's an exciting time for new tuberculosis (TB) vaccine development: several candidates are in late-stage development, with Phase 3 trial data available as early as 2024 and potential licensure and use in some countries in the near future. However, given differences in trial design, primary endpoints, target populations, and product attributes, none of the candidates is expected to be a "silver bullet." Moreover, without a known correlate of protection, the effect of HIV status, infection status, age and geography on vaccine efficacy must be determined for each new vaccine. We also need to ensure that the early pipeline remains robust in terms of new antigenic targets and platforms, and that new tools are developed to effectively evaluate their potential efficacy.

This webinar will bring together experts to discuss the status of TB vaccine development across the value chain, from the articulation of the public health and economic need for new TB vaccines, through to the status and strategies for product development, and on to the considerations for approval, policy recommendation and use.

PART 1: BCG is not enough

PART 2: TB vaccines for adults and adolescents on the horizon

PART 3: Innovation and new tools in TB vaccine development

PART 4: Preparing for success

Panel discussions will consider:

- What are the major bottlenecks to TB vaccine development for this new population, and what is needed to de-risk investment?
- Do we have the tools needed to identify and down-select new TB vaccine targets?
- What are the priorities to prepare the pathway for new TB vaccine implementation, particularly for adults and adolescents?

Latest information and materials from past meetings are available at:
https://www.technet-21.org/en/hot-topics-items/15105-gvirf

Questions? Please email gvirf@who.int

NIH National Institute of Allergy and Infectious Diseases

BILL & MELINDA GATES foundation

World Health Organization